25 LONG TERM – 8 YEAR FOLLOW UP OF A RANDOMIZED TRIAL OF TACROLIMUS MONOTHERAPY VERSUS TRIPLE THERAPY AFTER LIVER TRANSPLANTATION FOR HCV CIRRHOSIS

Preliminary results show SVR-4 is achieved in 41.2%, but the majority of responders remain on treatment.SVR-4 rates were 70% among those with eRVR, and this may be important predictor of response.These results must be balanced with high rates of AEs, including a mortality risk (2%).Improving tolerability and identifying predictors of SVR are critical to optimizing the risksbenefits of TT.Table 1: Virologic response by intent to treat